Cubist Systematic Strategies, LLC Protalix Bio Therapeutics, Inc. Transaction History
Cubist Systematic Strategies, LLC
- $14.3 Billion
- Q2 2024
A detailed history of Cubist Systematic Strategies, LLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 32,031 shares of PLX stock, worth $33,632. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,031
Previous 32,031
-0.0%
Holding current value
$33,632
Previous $37,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
5.61MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$851,7180.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$844,8300.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$485,0550.0% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$444,3730.0% of portfolio
-
Gsa Capital Partners LLP London, X0401KShares$421,3060.03% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $52.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...